Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

Key Points

• Wall Street Zen downgraded Monopar Therapeutics to “Sell” from “Hold,” while Zacks Research also lowered its view to “Hold.”
• Analyst sentiment remains broadly positive despite the downgrades: MarketBeat lists a “Moderate Buy” consensus and an average price target of $117.42, with several firms raising targets as high as $133.
• MNPR opened at $113.04 and remains near its 52-week high of $124.82. The company reported a quarterly loss of $0.62 per share, slightly better than the expected $0.64 loss, but analysts still project a full-year loss.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Sunday.

Other research analysts have also recently issued research reports about the company. Zacks Research cut Monopar Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday. HC Wainwright increased their target price on shares of Monopar Therapeutics from $105.00 to $125.00 and gave the stock a "buy" rating in a report on Wednesday, July 22nd. Cantor Fitzgerald downgraded shares of Monopar Therapeutics from an "overweight" rating to a "neutral" rating and raised their price target for the company from $109.00 to $119.00 in a research note on Thursday. Barclays reaffirmed an "overweight" rating and set a $128.00 price target (up from $125.00) on shares of Monopar Therapeutics in a report on Thursday. Finally, BTIG Research upped their price objective on shares of Monopar Therapeutics from $117.00 to $133.00 and gave the stock a "buy" rating in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $117.42.

Monopar Therapeutics Stock Performance

NASDAQ MNPR opened at $113.04 on Friday. The firm has a 50-day simple moving average of $96.11 and a 200 day simple moving average of $71.53. The stock has a market cap of $758.50 million, a PE ratio of -52.09 and a beta of 1.47. Monopar Therapeutics has a twelve month low of $29.18 and a twelve month high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. Research analysts forecast that Monopar Therapeutics will post -2.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Monopar Therapeutics

Several large investors have recently bought and sold shares of MNPR. Janus Henderson Group PLC boosted its stake in shares of Monopar Therapeutics by 2.3% during the fourth quarter. Janus Henderson Group PLC now owns 1,317,410 shares of the company's stock valued at $85,908,000 after purchasing an additional 30,042 shares in the last quarter. RA Capital Management L.P. increased its stake in shares of Monopar Therapeutics by 30.5% in the fourth quarter. RA Capital Management L.P. now owns 667,207 shares of the company's stock valued at $43,569,000 after buying an additional 156,000 shares during the period. Siren L.L.C. raised its holdings in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company's stock valued at $14,800,000 after buying an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC raised its holdings in Monopar Therapeutics by 13.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock valued at $14,480,000 after buying an additional 30,370 shares during the last quarter. Finally, Wellington Management Group LLP acquired a new stake in Monopar Therapeutics during the 3rd quarter worth approximately $18,904,000. 1.83% of the stock is currently owned by institutional investors.

Key Headlines Impacting Monopar Therapeutics

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: BTIG raised its price target to $133. The target is above MNPR’s recent trading level and signals continued confidence in the company’s outlook. BTIG Research Boosts Monopar Therapeutics Price Target
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $125 price target. The firm increased its long-term EPS forecasts to $2.44 for fiscal 2029 and $6.77 for fiscal 2030, suggesting expectations for substantial future profitability. HC Wainwright Monopar Therapeutics Estimates
• Positive Sentiment: Recent quarterly results exceeded expectations. Monopar reported a quarterly loss of $0.62 per share versus the $0.64 loss analysts expected, providing a modest near-term earnings positive. Monopar Therapeutics Quarterly Earnings
• Neutral Sentiment: Analysts continue to assess MNPR alongside other healthcare companies. A market commentary featuring Monopar did not identify a specific new company catalyst, leaving the report’s direct impact on the stock limited. Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright reduced its near-term EPS forecasts. Estimates were lowered for Q3 2026 to a $0.90 loss, Q4 to a $1.08 loss, and fiscal 2026 to a $3.07 loss. Forecasts for fiscal 2027 and 2028 were also trimmed, indicating continued cash-burn and profitability risks. HC Wainwright Lowers Monopar EPS Estimates
• Negative Sentiment: Zacks Research downgraded Monopar from Strong Buy to Hold. The less favorable rating may weigh on sentiment, particularly after the stock’s substantial rise and proximity to its 52-week high. Zacks Downgrades Monopar Therapeutics

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company's core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company's pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source